SSG
ALNY icon

Summit Securities Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Summit Securities Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-202
Closed -$80.3K – 1032
2025
Q4 		$80.3K Buy
+202
New +$89.4K 0.01% 517
2024
Q4 		– Sell
-1
Closed – – 615
2024
Q3 		$0 Buy
+1
New +$260 ﹤0.01% 547
2023
Q1 		– Sell
-1
Closed – – 788
2022
Q4 		$0 Buy
+1
New +$213 ﹤0.01% 1138
2015
Q1 		– Sell
-100
Closed -$10K – 382
2014
Q4 		$10K Buy
+100
New +$9.27K ﹤0.01% 448
2013
Q3 		– Sell
-100
Closed -$3K – 416
2013
Q2 		$3K Buy
+100
New +$2.66K ﹤0.01% 440

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Summit Securities Group's ALNY Position: Q1 2026 in Review

Summit Securities Group sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 202 shares — an estimated $80.3K sold.

Summit Securities Group first reported a position in ALNY in Q2 2013 and held it in 5 quarters. The position peaked at $80.3K in Q4 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Summit Securities Group reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Summit Securities Group sold 202 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $80.3K.
  • Summit Securities Group first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 5 quarters.
  • Summit Securities Group's Alnylam Pharmaceuticals position peaked at $80.3K in Q4 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Summit Securities Group's 13F filing for Q1 2026, filed 30 Apr 2026.